BAY y5959 is a new class of positive inotropic agent, structurally similar to the dihydropyridine calcium channel blockers. It is believed to work as a calcium agonist and has been associated with increased dP/dT in animal models and humans with heart failure. The current study aims to better characterize the safety, pharmacokinetics, and pharmacodynamics in patients with advanced CHF.
Showing the most recent 10 out of 1103 publications